Bioharvest Sciences vs Voyager Therapeutics
Voyager Therapeutics is the larger business, with $40.4m of revenue in fiscal 2025 against $34.5m for Bioharvest Sciences (1.2 times as much). Bioharvest Sciences grew faster (37.0% against -49.5%). Bioharvest Sciences kept more of each dollar of sales as profit: a net margin of -32.3% against -296.5%. Voyager Therapeutics carries less debt relative to equity (0.0% against 0.6%).
| Latest fiscal year | Bioharvest SciencesBHST, 2025 | Voyager TherapeuticsVYGR, 2025 |
|---|---|---|
| Revenue | $34.5m | $40.4m |
| Revenue growth | 37.0% | -49.5% |
| Net income | −$11.1m | −$120m |
| Operating margin | -16.2% | -326.6% |
| Net margin | -32.3% | -296.5% |
| Return on equity | -83.2% | -48.3% |
| Free cash flow | −$9.6m | −$135m |
| Cash | $23.0m | $65.3m |
| Total debt | $149,000 | $0 |
| Debt to equity | 0.6% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 141 |
| Market value | $34.7m | $110m |
| Price vs our value range | — | — |
| Moat score | — | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 11 sales |